What happened The FirstLight studies (168 participants, three dose arms) and RadiantLight (105 participants, two arms) evaluated oveporexton twice daily for 12 weeks compared to placebo.
Oveporexton, the drug that mimics orexin, passes phase 3 for type 1 narcolepsy - Sinaptica
Two phase 3 trials published this week in The New England Journal of Medicine confirm that oveporexton, an oral drug developed by Takeda, significantly reduces
sinapti.ca
September 27, 2026 at 1:17 AM
What happened The FirstLight studies (168 participants, three dose arms) and RadiantLight (105 participants, two arms) evaluated oveporexton twice daily for 12 weeks compared to placebo.
The latest video in our partnership with @glaucomflecken.bsky.social summarizes recent research into the efficacy and safety of oveporexton for the treatment of narcolepsy type 1. Access the article for free: nej.md/DrG23
August 12, 2025 at 7:02 PM
The latest video in our partnership with @glaucomflecken.bsky.social summarizes recent research into the efficacy and safety of oveporexton for the treatment of narcolepsy type 1. Access the article for free: nej.md/DrG23
Patients with narcolepsy type 1 have hypersomnolence caused by a loss of orexin-producing neurons. Research findings from the TAK-861-2001 trial on oveporexton, a highly selective oral orexin receptor 2 agonist, in these patients are summarized in a new Quick Take video. nej.md/4mdFZUS
#MedSky
#MedSky
May 24, 2025 at 12:01 PM
Patients with narcolepsy type 1 have hypersomnolence caused by a loss of orexin-producing neurons. Research findings from the TAK-861-2001 trial on oveporexton, a highly selective oral orexin receptor 2 agonist, in these patients are summarized in a new Quick Take video. nej.md/4mdFZUS
#MedSky
#MedSky
Current therapies for narcolepsy type 1 do not target orexin deficiency or treat all symptoms. Oveporexton, an oral orexin receptor 2−selective agonist, has shown efficacy in a phase 2 trial. Research findings from two phase 3 trials are summarized in a new Quick Take video. https://nej.md/4AsoBTE
September 30, 2026 at 1:00 PM
Current therapies for narcolepsy type 1 do not target orexin deficiency or treat all symptoms. Oveporexton, an oral orexin receptor 2−selective agonist, has shown efficacy in a phase 2 trial. Research findings from two phase 3 trials are summarized in a new Quick Take video. https://nej.md/4AsoBTE
In the First Light and Radiant Light trials, oveporexton improved wakefulness, reduced daytime sleepiness, and lowered the cataplexy rate among patients with narcolepsy type 1. Increased urinary frequency and transient insomnia were common. Full results and Research Summary: https://nej.md/4gvhEZZ
September 28, 2026 at 7:00 PM
In the First Light and Radiant Light trials, oveporexton improved wakefulness, reduced daytime sleepiness, and lowered the cataplexy rate among patients with narcolepsy type 1. Increased urinary frequency and transient insomnia were common. Full results and Research Summary: https://nej.md/4gvhEZZ
New in NEJM: two phase 3 randomized placebo-controlled trials tested oveporexton in 273 people with narcolepsy type 1. (1/5)
October 1, 2026 at 4:05 PM
New in NEJM: two phase 3 randomized placebo-controlled trials tested oveporexton in 273 people with narcolepsy type 1. (1/5)
Takeda Pharmaceutical’s experimental narcolepsy drug has significantly improved outcome for patients in late-stage clinical trials, and could become the first treatment to target the disorder's root cause.
Takeda nears first therapy for root cause of narcolepsy
Patients who took the drug, called oveporexton, for 12 weeks experienced increased daytime alertness and an overall improvement in quality of life.
ebx.sh
September 9, 2025 at 3:52 AM
Takeda Pharmaceutical’s experimental narcolepsy drug has significantly improved outcome for patients in late-stage clinical trials, and could become the first treatment to target the disorder's root cause.
Qué pasó Los estudios FirstLight (168 participantes, tres brazos de dosis) y RadiantLight (105 participantes, dos brazos) evaluaron oveporexton dos veces al día durante 12 semanas frente a placebo.
Oveporexton, el fármaco que imita la orexina, supera la fase 3 contra la narcolepsia tipo 1 - Sinaptica
Dos ensayos de fase 3 publicados esta semana en The New England Journal of Medicine confirman que oveporexton, un fármaco oral desarrollado por Takeda, reduce d
sinapti.ca
September 27, 2026 at 1:18 AM
Qué pasó Los estudios FirstLight (168 participantes, tres brazos de dosis) y RadiantLight (105 participantes, dos brazos) evaluaron oveporexton dos veces al día durante 12 semanas frente a placebo.
First Light and Radiant Light: In two placebo-controlled trials, oveporexton improved wakefulness, reduced daytime sleepiness, and lowered the cataplexy rate among patients with narcolepsy type 1. Increased urinary frequency and transient insomnia were common. Full results: https://nej.md/4gvhEZZ
September 9, 2026 at 12:05 PM
First Light and Radiant Light: In two placebo-controlled trials, oveporexton improved wakefulness, reduced daytime sleepiness, and lowered the cataplexy rate among patients with narcolepsy type 1. Increased urinary frequency and transient insomnia were common. Full results: https://nej.md/4gvhEZZ
Is it a wake-up call? The just published trial in NEJM of a new Orexin drug may be a game changer for narcolepsy. The results have rocked the sleep medicine world. Oveporexton (TAK-861) targeted the orexin system to treat narcolepsy type 1. Restored alertness and reduced cataplexy.
June 14, 2025 at 3:43 AM
Is it a wake-up call? The just published trial in NEJM of a new Orexin drug may be a game changer for narcolepsy. The results have rocked the sleep medicine world. Oveporexton (TAK-861) targeted the orexin system to treat narcolepsy type 1. Restored alertness and reduced cataplexy.
Narkolepsie-Patienten warten meist viele Jahre auf ihre Diagnose. Doch eine kausale Therapie gibt es dann trotzdem nicht – bis jetzt. Mit Oveporexton steht ein neuer Wirkstoff bereit, der genau dort ansetzt, wo das Problem beginnt. docc.hk/f6qks8
Narkolepsie: Einschlafen war gestern
Narkolepsie-Patienten warten meist viele Jahre auf ihre Diagnose. Doch eine kausale Therapie gibt es dann trotzdem nicht – bis jetzt. Mit Oveporexton steht ein neuer Wirkstoff bereit, der genau dort a...
docc.hk
April 15, 2026 at 3:28 PM
Narkolepsie-Patienten warten meist viele Jahre auf ihre Diagnose. Doch eine kausale Therapie gibt es dann trotzdem nicht – bis jetzt. Mit Oveporexton steht ein neuer Wirkstoff bereit, der genau dort ansetzt, wo das Problem beginnt. docc.hk/f6qks8
Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials www.nejm.org/doi/full/10....
Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials | NEJM
Narcolepsy type 1 is characterized by excessive daytime sleepiness, cataplexy, disrupted sleep, sleep paralysis, and hypnagogic or hypnopompic hallucinations. Oveporexton (TAK-861), an oral orexin ...
www.nejm.org
September 16, 2026 at 12:47 PM
Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials www.nejm.org/doi/full/10....
In the TAK-861-2001 trial involving 112 participants with narcolepsy type 1, oveporexton significantly improved measures of wakefulness, sleepiness, and cataplexy over a period of 8 weeks. Full trial results and Research Summary: nej.md/3ZdlKNi
#MedSky #NeuroSky
#MedSky #NeuroSky
May 26, 2025 at 1:33 PM
In the TAK-861-2001 trial involving 112 participants with narcolepsy type 1, oveporexton significantly improved measures of wakefulness, sleepiness, and cataplexy over a period of 8 weeks. Full trial results and Research Summary: nej.md/3ZdlKNi
#MedSky #NeuroSky
#MedSky #NeuroSky
"Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials."
Publié ce jour dans le @nejm.org.
#MedSky #NeuroSky
www.nejm.org/doi/full/10....
Publié ce jour dans le @nejm.org.
#MedSky #NeuroSky
www.nejm.org/doi/full/10....
Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials | NEJM
Narcolepsy type 1 is characterized by excessive daytime sleepiness, cataplexy, disrupted sleep, sleep paralysis, and hypnagogic or hypnopompic hallucinations. Oveporexton (TAK-861), an oral orexin ...
www.nejm.org
September 24, 2026 at 12:44 PM
"Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials."
Publié ce jour dans le @nejm.org.
#MedSky #NeuroSky
www.nejm.org/doi/full/10....
Publié ce jour dans le @nejm.org.
#MedSky #NeuroSky
www.nejm.org/doi/full/10....
A New Drug Lifts the Fog of Sleepiness for Those With Narcolepsy (The New York Times) nej.md/4jsD4ZA
Original Article: Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials nej.md/4gvhEZZ
Original Article: Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials nej.md/4gvhEZZ
September 30, 2026 at 3:05 PM
A New Drug Lifts the Fog of Sleepiness for Those With Narcolepsy (The New York Times) nej.md/4jsD4ZA
Original Article: Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials nej.md/4gvhEZZ
Original Article: Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials nej.md/4gvhEZZ
In the TAK-861-2001 trial involving 112 participants with narcolepsy type 1, oveporexton significantly improved measures of wakefulness, sleepiness, and cataplexy over a period of 8 weeks. Full trial results: nej.md/3ZdlKNi
#MedSky #NeuroSky
#MedSky #NeuroSky
May 14, 2025 at 9:40 PM
In the TAK-861-2001 trial involving 112 participants with narcolepsy type 1, oveporexton significantly improved measures of wakefulness, sleepiness, and cataplexy over a period of 8 weeks. Full trial results: nej.md/3ZdlKNi
#MedSky #NeuroSky
#MedSky #NeuroSky
"Oveporexton significantly improved measures of wakefulness, sleepiness, and cataplexy over a period of 8 weeks" www.nejm.org/doi/full/10....
Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1 | NEJM
Narcolepsy type 1 is a disorder of hypersomnolence caused by a loss of orexin neurons,
which results in low orexin levels in the brain. In this phase 2, randomized, placebo-controlled
trial, partic...
www.nejm.org
May 15, 2025 at 9:15 AM
"Oveporexton significantly improved measures of wakefulness, sleepiness, and cataplexy over a period of 8 weeks" www.nejm.org/doi/full/10....
New in the May 15/22, 2025, issue of NEJM:
Tolebrutinib in Secondary Progressive MS (HERCULES trial) nej.md/4l3N9e5
Tolebrutinib vs. Teriflunomide in Multiple Sclerosis (GEMINI 1 and GEMINI 2 trials) nej.md/3FFDSIH
Oveporexton in Narcolepsy Type 1 (TAK-861-2001 trial) nej.md/3ZdlKNi
#MedSky
Tolebrutinib in Secondary Progressive MS (HERCULES trial) nej.md/4l3N9e5
Tolebrutinib vs. Teriflunomide in Multiple Sclerosis (GEMINI 1 and GEMINI 2 trials) nej.md/3FFDSIH
Oveporexton in Narcolepsy Type 1 (TAK-861-2001 trial) nej.md/3ZdlKNi
#MedSky
May 15, 2025 at 2:10 PM
New in the May 15/22, 2025, issue of NEJM:
Tolebrutinib in Secondary Progressive MS (HERCULES trial) nej.md/4l3N9e5
Tolebrutinib vs. Teriflunomide in Multiple Sclerosis (GEMINI 1 and GEMINI 2 trials) nej.md/3FFDSIH
Oveporexton in Narcolepsy Type 1 (TAK-861-2001 trial) nej.md/3ZdlKNi
#MedSky
Tolebrutinib in Secondary Progressive MS (HERCULES trial) nej.md/4l3N9e5
Tolebrutinib vs. Teriflunomide in Multiple Sclerosis (GEMINI 1 and GEMINI 2 trials) nej.md/3FFDSIH
Oveporexton in Narcolepsy Type 1 (TAK-861-2001 trial) nej.md/3ZdlKNi
#MedSky
New online! Benefits of oveporexton in narcolepsy type 1
Benefits of oveporexton in narcolepsy type 1
Nature Reviews Neurology, Published online: 09 June 2025; doi:10.1038/s41582-025-01109-3The oral orexin receptor 2-selective agonist oveporexton ameliorates the symptoms of narcolepsy type 1, according to a phase II trial.
bit.ly
June 9, 2025 at 8:32 PM
New online! Benefits of oveporexton in narcolepsy type 1
Narcolepsy's Lost Signal Gets Restored: FDA Approves First Orexin-Targeting Drug
Like, share, follow.
https://1ban.news/orzeyful-oveporexton-narcolepsy-type1-fda/
#1ban #orzeyful #oveporexton #sleep
Like, share, follow.
https://1ban.news/orzeyful-oveporexton-narcolepsy-type1-fda/
#1ban #orzeyful #oveporexton #sleep
August 7, 2026 at 6:11 PM
Narcolepsy's Lost Signal Gets Restored: FDA Approves First Orexin-Targeting Drug
Like, share, follow.
https://1ban.news/orzeyful-oveporexton-narcolepsy-type1-fda/
#1ban #orzeyful #oveporexton #sleep
Like, share, follow.
https://1ban.news/orzeyful-oveporexton-narcolepsy-type1-fda/
#1ban #orzeyful #oveporexton #sleep
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People wi...
Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org
#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org
#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
June 15, 2026 at 5:31 PM
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People wi...
Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org
#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org
#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
Orexin receptor agonist secures landmark narcolepsy approval
nature.com/articles/d41...
As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists
nature.com/articles/d41...
As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists
August 10, 2026 at 2:13 PM
Orexin receptor agonist secures landmark narcolepsy approval
nature.com/articles/d41...
As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists
nature.com/articles/d41...
As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists
Oveporexton dramatically enhances wakefulness and significantly reduces cataplexy in narcolepsy type 1, despite notable side effects.
by Dauvilliers Y, Mignot E (...) Plazzi G et 35 al. in N Engl J Med #MedSky
👉 get more here
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2601598
by Dauvilliers Y, Mignot E (...) Plazzi G et 35 al. in N Engl J Med #MedSky
👉 get more here
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2601598
September 18, 2026 at 8:52 PM
Oveporexton dramatically enhances wakefulness and significantly reduces cataplexy in narcolepsy type 1, despite notable side effects.
by Dauvilliers Y, Mignot E (...) Plazzi G et 35 al. in N Engl J Med #MedSky
👉 get more here
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2601598
by Dauvilliers Y, Mignot E (...) Plazzi G et 35 al. in N Engl J Med #MedSky
👉 get more here
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2601598
#BREAKING: The FDA has approved ORZEYFUL (oveporexton) on August 5, 2026, making it the first #orexin agonist approved for adults living with #narcolepsy type 1 in the United States.
🧠✨
To read more, visit project-sleep.com/orzeyful-fda...
#Breakthrough #Health #Medsky #SleepMedicine #Neurology
🧠✨
To read more, visit project-sleep.com/orzeyful-fda...
#Breakthrough #Health #Medsky #SleepMedicine #Neurology
August 5, 2026 at 11:00 PM
#BREAKING: The FDA has approved ORZEYFUL (oveporexton) on August 5, 2026, making it the first #orexin agonist approved for adults living with #narcolepsy type 1 in the United States.
🧠✨
To read more, visit project-sleep.com/orzeyful-fda...
#Breakthrough #Health #Medsky #SleepMedicine #Neurology
🧠✨
To read more, visit project-sleep.com/orzeyful-fda...
#Breakthrough #Health #Medsky #SleepMedicine #Neurology
I was (for obvious reasons) too tired yesterday to post this like I meant, but yesterday the FDA announced the approval of the new orexin agonist for narcolepsy and I'm overjoyed www.fda.gov/news-events/...
FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms
The FDA approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults.
www.fda.gov
August 6, 2026 at 4:40 PM
I was (for obvious reasons) too tired yesterday to post this like I meant, but yesterday the FDA announced the approval of the new orexin agonist for narcolepsy and I'm overjoyed www.fda.gov/news-events/...